Avacta Group widens half-year losses as sales slow

Animal and human healthcare company Avacta Group widened its half-year losses as revenues slowed during the introduction of new Optim analytical devices.

Animal and human healthcare company Avacta Group widened its half-year losses as revenues slowed during the introduction of new Optim analytical devices.

The provider of analytical and diagnostic technologies to the pharmaceutical and animal healthcare sectors, posted an operating loss of £0.97m in the six months to the end of January, up from £0.52m the previous year.

Revenues dropped to £1.15m from £1.72m during the transition from Optim1 to Optim2, an analytical instrument designed to probe multiple protein stability-indicating parameters.

The company has received orders for 10 units since launching the product on February 1st.

During the period, the company invested in training its sales team at ForteBio, the the newly acquired subsidiary of partner Pall Corporation. ForteBio is the key distributor for the US market of the Optim product.

"Revenues fell because Optim sales slowed as we introduced Optim2 and trained up the sales team at ForteBiom," Chief Executive Officer Alastair Smith told Digital Look and Sharecast.

He said it was a transformational period for the company which resulted in a short-term slowdown that will drive performance in the long run.

The company expects to launch its new Affimer reagents next year as development remains in line with management's expectations.

"The antibody replacement technology presents a lot of growth opportunities," he said.

"Over the next half we anticipate further progress across all divisions."

RD

Recommended

Imperial Brands has an 8.3% yield – but what’s the catch?
Share tips

Imperial Brands has an 8.3% yield – but what’s the catch?

Tobacco company Imperial Brands boasts an impressive dividend yield, and the shares look cheap. But investors should beware, says Rupert Hargreaves. H…
20 May 2022
Investing in drugmakers: uncommon profits from curing rare diseases
Share tips

Investing in drugmakers: uncommon profits from curing rare diseases

Treatments for medical conditions with only a small number of sufferers can still be very attractive for pharmaceutical companies and investors becaus…
20 May 2022
Share tips of the week – 20 May
Share tips

Share tips of the week – 20 May

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
20 May 2022
Delivering profits: should you buy Royal Mail shares?
Share tips

Delivering profits: should you buy Royal Mail shares?

The volume of parcels delivered by Royal Mail soared during the pandemic, and so did its profits. But it has been coming under pressure lately. So, as…
19 May 2022

Most Popular

The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves looks at the FTSE 100’s top yielding stocks for income investors to consider.
18 May 2022
Aviva: a share for income investors to tuck away
Share tips

Aviva: a share for income investors to tuck away

Insurance giant Aviva is one of the highest yielding stocks in the FTSE 100 – and it’s cheap, too, making it a tempting target for income investors. R…
18 May 2022
Despite the crypto crash, bitcoin still has a bright future
Bitcoin & crypto

Despite the crypto crash, bitcoin still has a bright future

Cryptocurrencies have crashed hard, with bitcoin down by more than 50% from its peak. But, says Dominic Frisby, bitcoin still has a future – it is the…
19 May 2022